The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line iparomlimab and tuvonralimab (QL1706) or iparomlimab (QL1604) + bevacizumab (BEV) for unresectable hepatocellular carcinoma (HCC): Updated results from the phase Ib/II DUBHE-H-106 study.
 
Feng Bi
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Yabing Guo
No Relationships to Disclose
 
Zhongyuan Xu
No Relationships to Disclose
 
Shanzhi Gu
No Relationships to Disclose
 
Yao Huang
No Relationships to Disclose
 
Mingxu Da
No Relationships to Disclose
 
Zhiyu Chen
No Relationships to Disclose
 
Chaoying Liu
No Relationships to Disclose
 
Yaozhen Pan
No Relationships to Disclose
 
Hao Ying
No Relationships to Disclose
 
Ming Huang
No Relationships to Disclose
 
Zheng Wang
No Relationships to Disclose
 
Jianbing Wu
No Relationships to Disclose
 
Jun Zhao
No Relationships to Disclose
 
Ranran Sun
No Relationships to Disclose
 
Shujun Yang
No Relationships to Disclose
 
Xiaokui Yu
Employment - Qilu Pharmaceutical Co., Ltd. (Jinan, China)
 
Hui Li
Employment - Qilu Pharmaceutical Co., Ltd. (Jinan, China)
 
Shilin Xue
Employment - Qilu Pharmaceutical Co., Ltd. (Jinan, China)